Treatment of functional gut symptoms in patients with quiescent inflammatory bowel disease and irritable bowel syndrome - A single-blinded parallel trial assessing efficacy of app-delivered gut-directed hypnotherapy versus psychoeducatio

Not Applicable

• Conditions: Inflammatory Bowel Disease; Irritable Bowel Syndrome; Oral and Gastrointestinal - Inflammatory bowel disease; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon

• Registration Number: ACTRN12624000678594
• Lead Sponsor: Monash University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-28
• Last Update Posted: 3 June 2024

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 126

Inclusion Criteria

Adults patients with quiescent IBD (determined by intestinal ultrasound (IUS)), and IBS (based on Rome criteria), who are on stable IBD therapy for at least two months.

Exclusion Criteria

Exclusion criteria comprises patients unsuitable for IUS (e.g., obesity, predominant rectal disease), active IBD, coeliac disease, new IBS therapies for the prior four weeks, including change in diet, supplementary probiotics, prebiotics or any medication unrelated to IBD treatment, that might influence GI function, rectal disease with constipation, pregnancy or breastfeeding, ineligibility for Medicare or inability to speak or read English or give informed consent.

Study & Design

• Study Type: Interventional
• Study Design: Not specified